AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01101360 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse Dye Laser followed by Matrix RF
Description: Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
Study NCT03629860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrophic maxillary alveolar ridge augmentation
Description: Autogenous bone blocks from chin and ascending ramus are obtained and used for reconstruction of atrophic maxillary ridges
Study NCT02875275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose with grass jelly solution
Description: 50 g glucose and 3.12 g grass jelly dissolve in water (top up to 200g)
Study NCT02875275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose with grass jelly (solid)
Description: 50 g glucose and 3.12 g grass jelly and 3.12g starch dissolve in hot water (top up to 200g)
Study NCT02875275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Porridge and juice with coconut oil
Description: Add instant porridge with hot water with oil. Consume with commercially available orange juice
Study NCT02875275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Porridge and juice with coconut oil gel
Description: Add instant porridge with hot water with oleogel. Consume with commercially available orange juice
Study NCT05680961 — intervention group
Intervention type: DEVICE
Intervention: Monitoring Device
Description: Monitoring Device
Study NCT04122391 — intervention group
Intervention type: OTHER
Intervention: sound level volume
Description: Noise level during cardiac arrest
Study NCT02889601 — intervention group
Intervention type: OTHER
Intervention: Psycho-behavioural assessment
Description: DAPHNE Scale
Study NCT03254160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNS-3379
Description: DNS-3379
Study NCT03254160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04701528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin
Description: Temporarily switching of tacrolimus maintenance immunosuppression to voclosporin maintenance immunosuppression with possible additional anti-viral activity
Study NCT04701528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Comparator
Study NCT02112760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific stabilization exercise
Description: The specific stabilization exercise refers to an exercise that targets the deep trunk muscle, including the multifidus and transversus abdominis with ultrasound feedback.
Study NCT02653573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Self-management education
Study NCT00594191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met
Study NCT00594191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with the same characteristics of the drug and at the same dose
Study NCT01422369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin (NK-104)
Description: Pitavastatin (NK-104) 4mg once daily (QD)
Study NCT01422369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir (Prezista)
Description: Darunavir/Ritonavir (Prezista) 800 mg/100 mg
Study NCT01028261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZGN-433
Description: Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
Study NCT01685125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abiraterone acetate
Description: Given PO
Study NCT01685125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Given PO
Study NCT01685125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given PO
Study NCT01685125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Given PO
Study NCT01685125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT00280709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nitinella ; SX-ELLA Stent Biliary (biliary metal stent)
Description: Nitinella covered (arm 1) or uncovered (arm 2) biliary metal stent. Maximum diameter 10 mm, length 52 or 72 mm
Study NCT03441919 — intervention group
Intervention type: RADIATION
Intervention: PET-CT (positron emission tomography - computer tomography)
Description: PET-CT to determine vascular inflammation
Study NCT03441919 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood drawn
Description: Blood drawn
Study NCT00888394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chiropody
Description: basic procedure of chiropody in podiatry
Study NCT00888394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: basic orthesis
Description: individual basic orthesis of foot
Study NCT00888394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: advantage orthesis
Description: advantage orthesis of foot with special material and design
Study NCT00888394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chiropody and advantage orthesis
Description: chiropody and advantage orthesis of foot
Study NCT02231814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crohns Disease Exclusion Diet + PEN
Description: Patients will use the CDED for a 24 week period, coupled with 1000 ml of polymeric formula (1 Kcal/mL) for the first 6 weeks. For weeks 7 to 24 patients will use the CDED coupled with 600 ml formula and a calcium supplement. The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase.
Study NCT02231814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crohns Disease Exclusion Diet
Description: Crohn's Disease Exclusion Diet alone with a calcium supplement during the study (0-24). The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase.
Study NCT04494243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-214 10/600mg
Description: 1 tablet administered before the breakfast during 7 days
Study NCT04494243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10mg
Description: 1 tablet administered before the breakfast during 7 days
Study NCT03403556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvamibe
Description: Rosuvastatin 10mg/Ezetimibe10mg qd for 24 weeks
Study NCT03403556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monorova
Description: Rosuvastatin 20mg qd for 24 weeks
Study NCT00993018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443 (1 mg)
Description: JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
Study NCT00993018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443 (3 mg)
Description: JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
Study NCT00993018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443 (10 mg)
Description: JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
Study NCT00993018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive single injection of matching placebo every 28 days for up to 52 weeks.
Study NCT03597542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs and Carbohydrates
Description: Participants are asked to consume both egg based powder or maltodextrin dissolved in 500mL of water at two different time points at least one week apart. Participants will then submit to a venous blood draw to assess levels of cellular inflammation.
Study NCT03005483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Orthopedic Surgery was applied for the treatment of osseous disorders
Study NCT03005483 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orthopedic Surgery was applied for the treatment of osseous disorders
Study NCT02884219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
Study NCT02884219 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Expectative Management
Description: Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
Study NCT02884219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
Study NCT00588341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: At the start of the trial a core needle biopsy of a palpable tumor will be obtained percutaneously in the office after administration of local anesthesia. Patients will then be treated with TMZ according to the extended dosing schedule of 75mg/m2/day x 6 weeks every 8 weeks. After each cycle, patients will be re-evaluated for response.~Responding patients will be offered another cycle of treatment. Patients will be treated until best response, progression of disease, or 6 cycles, whichever comes first.~After completing temozolomide treatment, patients will be evaluated for surgical resection. It is expected that, unless there is progression of disease, patients will undergo resection (i.e. therapeutic lymph node dissection). In patients who have a complete clinical response to temozolomide, whether or not to do a subsequent lymph node dissection will be left up to the discretion of the surgeon and the patient.
Study NCT03230071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMBCZG
Description: 0.1g per pill which contains 14mg TMBCZG
Study NCT03230071 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.1g per pill which contains 0mg TMBCZG
Study NCT03230071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: 0.1g per pill which contains 0mg TMBCZG
Study NCT03472859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHOTOLASE
Description: This is the investigational yellow laser (PHOTOLASE)
Study NCT03472859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KTP
Description: This is the traditional green laser (KTP)
Study NCT03011554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Miniature Telescope (IMT)
Description: Monocular implantation of the IMT.
Study NCT03373500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary salt reduction
Description: Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
Study NCT04448821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Single administration of metformin
Study NCT04448821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Nilotinib
Description: Coadministration of metformin and nilotinib
Study NCT01028261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-433
Description: Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
Study NCT03352934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered as intravenous infusion at 10 mg/kg once every two weeks until documented disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawal are met.
Study NCT01462162 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Study NCT00058019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT04481828 — intervention group
Intervention type: PROCEDURE
Intervention: gastrectomy
Description: gastric resection with lymph node dissection(D1+,D2) for stomach cancer.
Study NCT00684762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg Tablets
Description: Cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours
Study NCT00684762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol (Pletal®) 100 mg Tablets
Description: Cilostazol (Pletal® 1 x 100mg tablet) administered after an overnight fast of at least 10 hours.
Study NCT02374632 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Meal tests after saline injection
Description: Fixed breakfast meal and ad libitum lunch meal
Study NCT02374632 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Meal tests after octreotide injection
Description: Fixed breakfast meal and ad libitum lunch meal
Study NCT02374632 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sham feeding
Study NCT04976114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Story book with information about surgery techniques
Description: Presurgery use of Story book. The parents with the child read a book with information about surgery techniques the days before surgery.
Study NCT04976114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video with information about surgery techniques
Description: Presurgery use of video. The parents with the child watch a video with information about surgery techniques the days before surgery.
Study NCT04976114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Story book and Video with information about surgery techniques
Description: Presurgery use of video and story book. The parents with the child watch a video and read a book (both) with information about surgery techniques the days before surgery.
Study NCT02360631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chantix
Description: A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.
Study NCT02360631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Health education counseling will be provided to all participants.
Study NCT01446133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.
Study NCT01446133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg/day by mouth daily beginning on Day 9 of cycle 1.
Study NCT03142152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carillon Mitral Contour System
Description: The Carillon implant is designed to be deployed, tensioned, and locked in the coronary vein in order to reshape the mitral annulus and thus reduce mitral annular dilation and mitral regurgitation.
Study NCT03142152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guideline Directed Heart Failure Medication
Description: Heart failure medication per ACC/AHA guidelines
Study NCT03142152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guideline Directed Heart Failure Medication
Description: Heart failure medication per ACC/AHA guidelines
Study NCT04604509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride Controlled-release
Description: Given PO
Study NCT04604509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Given via nicotine patch, lozenges, or gum
Study NCT04604509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04604509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive behavioral smoking cessation counseling
Study NCT04604509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Given PO
Study NCT04368039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normobaric Oxygen
Description: 40% FiO2 for 4 weeks
Study NCT04368039 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 21% FiO2 for 4 weeks
Study NCT02734680 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy(CCRT)
Description: Radiation and take gemcitabine(GEM)
Study NCT02734680 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy(SBRT)
Description: Stereotactic Radiotherapy(SBRT) (total dose: 45 Gy; single dose: 3 Gy; Frequency:15)
Study NCT02734680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Taking S-1 orally after radiation
Study NCT03541772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oncoxin-Viusid®
Description: Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and Oncoxin-Viusid® (75 ml/day) before/during/after both treatments
Study NCT03541772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and placebo (75ml/day) before/during/after both treatments
Study NCT04244435 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: coronary artery bypass grafting with and without cardiopulmonary bypass
Study NCT04244435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CABG
Description: coronary artery bypass grafting with and without cardiopulmonary bypass
Study NCT04244435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thoracic epidural analgesia
Description: thoracic epidural analgesia at the level of 1-10 thoracic vertebrae (ropivacainum 0,2-0,5% 5-10 ml/h)
Study NCT04244435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: analgesia of opioids
Description: Opioids will be used for perioperative analgesia
Study NCT03292601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cinch Smart Strap
Description: The study device is a small (with dimensions of 1.5 x 2 x 3/8 and weighing approximately 0.9-oz) Bluetooth-enabled and battery-powered monitor with Velcro strap that attaches to orthopaedic braces for scoliosis in place of the traditional strap and buckle. When the Velcro strap is tightened, the device measures tension in Newtons with the vector of force parallel to and away from the device, reflecting the pulling force required to keep the brace fitted on the patient.
Study NCT03292601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cinch Mobile App
Description: The Cinch App allows patients and parents to track and edit treatment information, sync data from the Cinch Smart Strap, and view compliance data. The app connects via Bluetooth to the Cinch Smart Strap and allows patients and parents save and sync data from the device.
Study NCT02872298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Lung Denervation (TLD)
Description: The Nuvaira Lung Denervation System, manufactured by Nuvaira, Inc., is intended to deliver TLD Therapy using predetermined radiofrequency (RF) energy over a predetermined period of time to ablate airway nerve trunks which are located on the outside of the main bronchi.
Study NCT04047511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRTierOne
Description: As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work.
Study NCT04047511 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group general fitness training
Description: A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Perception of effort will be monitored using the Borg 6-20 rating the perceived exertion. Conducted by a physiotherapist in group form.